molnupiravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5377 None

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • molnupiravir
  • EIDD-2801
  • N4-Hydroxycytidine
  • Beta-D-N4-hydroxycytidine
  • NHC
  • MK-4482
EIDD-1931 has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir
  • Molecular weight: 329.31
  • Formula: C13H19N3O7
  • CLOGP: -1.13
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 4
  • TPSA: 140.92
  • ALOGS: -1.81
  • ROTB: 6

Drug dosage:

DoseUnitRoute
1.60 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,TEK 19
kinase-selectivity-class GRK2,MAP2K6,PDK1 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 2021 PMDA MSD K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 950.20 46.11 264 3444 67718 90557021
Product use issue 735.92 46.11 325 3383 329594 90295145
Accidental underdose 680.59 46.11 101 3607 990 90623749
Product use complaint 529.25 46.11 96 3612 3437 90621302
Wrong technique in product usage process 527.19 46.11 170 3538 71401 90553338
COVID-19 287.54 46.11 139 3569 168704 90456035
Accidental overdose 260.91 46.11 80 3628 28193 90596546
Underdose 250.61 46.11 91 3617 53926 90570813
Product use in unapproved indication 186.76 46.11 134 3574 336102 90288637
Product prescribing issue 138.53 46.11 37 3671 7942 90616797
COVID-19 pneumonia 124.36 46.11 41 3667 18136 90606603
Product packaging quantity issue 111.93 46.11 23 3685 1579 90623160
Incorrect product administration duration 91.07 46.11 33 3675 19289 90605450
Overdose 76.18 46.11 58 3650 157651 90467088
Inappropriate schedule of product administration 72.10 46.11 55 3653 149878 90474861
Pneumonia aspiration 67.17 46.11 33 3675 40907 90583832
Toxic skin eruption 49.37 46.11 20 3688 15754 90608985
Poor quality product administered 48.45 46.11 14 3694 3994 90620745
Drug eruption 47.73 46.11 25 3683 35382 90589357

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 837.91 41.24 242 2963 38779 42579351
Product use issue 781.35 41.24 269 2936 76482 42541648
Accidental underdose 481.08 41.24 76 3129 595 42617535
COVID-19 338.77 41.24 167 3038 115781 42502349
Product use complaint 264.23 41.24 55 3150 2176 42615954
Product use in unapproved indication 248.53 41.24 160 3045 184296 42433834
Wrong technique in product usage process 238.33 41.24 97 3108 42538 42575592
Underdose 205.53 41.24 68 3137 16598 42601532
COVID-19 pneumonia 137.24 41.24 54 3151 21559 42596571
Product prescribing issue 113.75 41.24 35 3170 6738 42611392
Accidental overdose 113.46 41.24 51 3154 28279 42589851
Incorrect product administration duration 109.92 41.24 33 3172 5847 42612283
Product packaging quantity issue 85.79 41.24 20 3185 1333 42616797
Adverse event 53.86 41.24 29 3176 23611 42594519
Drug eruption 48.94 41.24 27 3178 23048 42595082
Pneumonia aspiration 46.95 41.24 35 3170 50043 42568087

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 1810.70 34.85 489 6458 73350 110509002
Product use issue 1414.35 34.85 576 6371 311119 110271233
Accidental underdose 1077.00 34.85 163 6784 1142 110581210
Product use complaint 792.42 34.85 146 6801 3657 110578695
Wrong technique in product usage process 768.98 34.85 264 6683 87084 110495268
COVID-19 588.28 34.85 292 6655 244768 110337584
Underdose 417.80 34.85 155 6792 63399 110518953
Product use in unapproved indication 410.52 34.85 286 6661 447091 110135261
Accidental overdose 350.03 34.85 129 6818 51705 110530647
COVID-19 pneumonia 245.29 34.85 91 6856 37052 110545300
Product prescribing issue 226.16 34.85 66 6881 12706 110569646
Incorrect product administration duration 187.56 34.85 64 6883 20434 110561918
Product packaging quantity issue 143.22 34.85 31 6916 1768 110580584
Pneumonia aspiration 113.49 34.85 68 6879 81165 110501187
Inappropriate schedule of product administration 100.78 34.85 91 6856 203546 110378806
Overdose 95.64 34.85 94 6853 233700 110348652
Drug eruption 93.82 34.85 52 6895 53607 110528745
Rash 57.10 34.85 145 6802 820819 109761533
Diarrhoea 54.72 34.85 176 6771 1139329 109443023
Dysphagia 52.28 34.85 56 6891 153544 110428808
Toxic skin eruption 48.99 34.85 27 6920 27488 110554864
Poor quality product administered 48.39 34.85 16 6931 4625 110577727
Product dose omission in error 47.24 34.85 25 6922 23487 110558865
Prescribed underdose 46.43 34.85 36 6911 65138 110517214
Symptom recurrence 44.01 34.85 15 6932 4757 110577595
Fatigue 42.47 34.85 12 6935 1215946 109366406
Product physical issue 39.39 34.85 14 6933 5022 110577330
Marasmus 35.56 34.85 10 6937 1681 110580671

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB18 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:149553 anticoronaviral agent

Related Drugs by ATC class:

J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
acyclovirbrivudinecidofovirfamciclovirgancicloviridoxuridinepenciclovirremdesivirvalaciclovirvalganciclovirvidarabine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
COVID-19 indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.55 acidic
pKa2 11.55 acidic
pKa3 13.03 acidic
pKa4 4.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
YA84KI1VEW UNII
3258-02-4 SECONDARY_CAS_RN
4041077 VANDF
C5435024 UMLSCUI
CHEBI:180653 CHEBI
XMO PDB_CHEM_ID
CHEMBL4650320 ChEMBL_ID
145996610 PUBCHEM_CID
DB15661 DRUGBANK_ID
11853 INN_ID
C000656703 MESH_SUPPLEMENTAL_RECORD_UI
C010737 MESH_SUPPLEMENTAL_RECORD_UI
10737 IUPHAR_LIGAND_ID
DB15660 DRUGBANK_ID
1201931008 SNOMEDCT_US
1201933006 SNOMEDCT_US
C0067182 UMLSCUI
D11943 KEGG_DRUG
354402 MMSL
40179 MMSL
d09837 MMSL
018901 NDDF
197020 PUBCHEM_CID
2492423-29-5 SECONDARY_CAS_RN
2587901 RXNORM
CHEBI:51369 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LAGEVRIO HUMAN PRESCRIPTION DRUG LABEL 1 0006-5055 CAPSULE 200 mg ORAL Emergency Use Authorization 31 sections